Edition:
United States

Samsung Biologics Co Ltd (207940.KS)

207940.KS on Korea Stock Exchange

303,500.00KRW
10:18pm EDT
Change (% chg)

₩-500.00 (-0.16%)
Prev Close
₩304,000.00
Open
₩300,000.00
Day's High
₩305,500.00
Day's Low
₩296,000.00
Volume
51,641
Avg. Vol
131,803
52-wk High
₩556,000.00
52-wk Low
₩281,000.00

About

SAMSUNG BIOLOGICS Co., Ltd. is a Korea-based company primarily engaged in development, manufacture and distribution of biological products. The Company, a contract manufacturing organization (CMO) mainly develops, manufactures antibody drugs, which are used for the treatment of cancer, autoimmune disease, diabetes and other... (more)

Overall

Beta: --
Market Cap(Mil.): ₩22,290,680.00
Shares Outstanding(Mil.): 66.17
Dividend: --
Yield (%): --

Financials

  207940.KS Industry Sector
P/E (TTM): -- 29.30 32.55
EPS (TTM): -2,575.29 -- --
ROI: -3.52 14.23 13.82
ROE: -4.65 15.46 15.24

South Korea watchdog says to appeal court move to suspend Samsung BioLogics' sanctions

SEOUL South Korea's top financial regulator, the Financial Services Commission (FSC), said on Tuesday it will file an appeal against a court decision to suspend sanctions on Samsung BioLogics Co Ltd.

Jan 29 2019

S.Korea watchdog says to appeal court move to suspend Samsung BioLogics' sanctions

SEOUL, Jan 29 South Korea's top financial regulator, the Financial Services Commission (FSC), said on Tuesday it will file an appeal against a court decision to suspend sanctions on Samsung BioLogics Co Ltd.

Jan 29 2019

South Korean court suspends regulator's disciplinary action against Samsung BioLogics

SEOUL A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd for allegedly breaching accounting rules, an official at the Seoul Administrative Court said on Tuesday.

Jan 22 2019

UPDATE 3-S.Korean court suspends regulator's disciplinary action against Samsung BioLogics

* Firm must now await outcome of prosecutors' investigation (Adds FSC's response on court's ruling)

Jan 22 2019

S.Korean court suspends regulator's disciplinary action against Samsung BioLogics

SEOUL, Jan 22 A South Korean court has suspended the financial regulator's disciplinary action against Samsung BioLogics Co Ltd over breach of accounting rules, an official at the Seoul Administrative Court said on Tuesday.

Jan 21 2019

South Korean prosecutors raid Samsung BioLogics' office in accounting probe

SEOUL Samsung BioLogics Co Ltd's on Thursday said its head office has been raided by South Korean prosecutors as part of a criminal probe into alleged accounting fraud.

Dec 13 2018

UPDATE 1-S.Korean prosecutors raid Samsung BioLogics' office in accounting probe

SEOUL, Dec 13 Samsung BioLogics Co Ltd's on Thursday said its head office has been raided by South Korean prosecutors as part of a criminal probe into alleged accounting fraud.

Dec 13 2018

S.Korean prosecutors raid Samsung Biologics' office in accounting probe

SEOUL, Dec 13 South Korean prosecutors on Thursday raided Samsung Biologics Co Ltd's head office outside of Seoul as part of a probe into alleged accounting fraud, the company said.

Dec 13 2018

S.Korea stocks flat; won slips on Brexit vote delay

* KOSPI index flat, foreigners sell * Won edges down against U.S. dollar * South Korea bond yields up SEOUL, Dec 11 Round-up of South Korean financial markets: ** South Korea's KOSPI stock index traded flat on Tuesday as sharp gains in Samsung BioLogics Co Ltd on resumption of trade offset losses caused by external uncertainties, including Brexit vote delay, and global growth concerns. The won fell while bond yields rose. ** Biotech d

Dec 10 2018

UPDATE 1-Samsung BioLogics shares to remain listed, resume trade on Dec. 11

SEOUL, Dec 10 South Korea's main stock exchange has decided Samsung BioLogics Co Ltd is qualified to continue trading on the exchange and that the company's shares will resume trading on Tuesday, the bourse said on Monday.

Dec 10 2018

Earnings vs. Estimates